Table of Contents
Kenneth Frazier, the first Black executive to lead a major pharmaceutical company, has seen the market value of his stake in Merck & Co. decline by millions of dollars following a recent plunge in the share price of the American multinational pharmaceutical company.
According to market data, Frazier, the former executive chairman and CEO of Merck & Co., has seen his stake in the New Jersey-based pharmaceutical giant slump by $6.42 million over the last three weeks, reflecting the recent decline in the company’s share price.
Merck shares slump seven percent as market cap dips below $310 billion
Merck & Co., a leading healthcare company, has solidified its place in the industry by offering a range of healthcare solutions, including prescription drugs, vaccines, biological therapies, animal health products, and consumer healthcare products. The company operates across three segments: pharmaceutical, animal health, and other.
The company’s shares on the New York Stock Exchange have seen a recent decline of 7.04 percent, falling from $129.45 on Feb. 23 to $120.34 at the time of this report. As a result, the company’s market capitalization has fallen below $310 billion, leading to significant losses for shareholders, including Frazier.
Black executive Kenneth Frazier’s Merck stake dips
Kenneth Frazier, a prominent Black executive in the U.S., holds a 0.028-percent stake in Merck & Co., currently valued at $84.9 million. Frazier’s total compensation from the pharmaceutical giant in 2022 declined 78.6 percent to $8.5 million, down from $15.2 million the prior year.
According to data tracked by Billionaires.Africa shows the market value of Frazier’s Merck stake has fallen by $6.42 million, slipping from $91.29 million on Feb. 23 to $84.87 million at the time of this report.
Despite the recent decline, Frazier remains a top Black executive, recognized for his strategic leadership and Merck’s commitment to innovation and sustainable healthcare solutions, which continue to attract investors.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now
